Why the study?
In functional mitral regurgitation, a leaflet coaptation gap caused by advanced left ventricular remodeling can be a potential exclusion criterion for MitraClip therapy.
Tailored anesthesiological and pharmacological management can facilitate successful MitraClip implantation in patients with severe functional mitral regurgitation and significant coaptation gaps that fall outside standard EVEREST criteria.
Answers are grounded in this paper and cite their sources.
May allow MitraClip beyond standard coaptation criteria with optimized management; hypothesis-generating case report requiring prospective validation.
Percutaneous mitral valve repair with the MitraClip system recently emerged as a viable and less invasive therapeutic option in patients with severe mitral regurgitation deemed to be high-risk surgical candidates. Mitral valve morphology and geometry features are key elements for MitraClip eligibility. In the setting of functional mitral regurgitation, the presence of a leaflet coaptation gap due to advanced left ventricle remodeling can be a potential exclusion criterion for MitraClip therapy. In this article, the authors present a case of successful MitraClip implantation in a patient with severe functional mitral regurgitation and a significant coaptation gap. Periprocedural and intraoperative pharmacological and anesthesiological management were fundamental for successful grasping and procedural success.
No takes yet. Share an insight, caveat, or question.
Mocavero et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: